Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, announced that on February 1, 2016, the compensation committee of the company’s board of directors granted 10 new employees options to purchase an aggregate of 17,800 shares of the company’s common stock with a per share exercise price of $18.86, the closing trading price on the grant date, and 8,900 restricted stock units.  The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company. (Original Source)

Shares of Relypsa closed yesterday at $18.25. RLYP has a 1-year high of $42.26 and a 1-year low of $10.26. The stock’s 50-day moving average is $23.29 and its 200-day moving average is $23.20.

On the ratings front, Relypsa has been the subject of a number of recent research reports. In a report issued on January 27, Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on RLYP, with a price target of $42, which implies an upside of 130.1% from current levels. Separately, on January 26, Oppenheimer’s Ling Wang reiterated a Buy rating on the stock and has a price target of $55.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Mara Goldstein and Ling Wang have a total average return of -14.5% and -24.1% respectively. Goldstein has a success rate of 26.5% and is ranked #3531 out of 3600 analysts, while Wang has a success rate of 11.1% and is ranked #3583.

Overall, one research analyst has rated the stock with a Sell rating, 11 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $48.29 which is 164.6% above where the stock closed yesterday.

Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.